

Biotech and Pharmaceutical Patents at the Federal Circuit

JANUARY 15, 2014

Join join other members of the local biotech, medical device and pharmaceutical industry for breakfast and a seminar discussion with Tara Elliott and Peter Fasse, who will recap several 2013 legal developments relevant to your industries.

Tara and Peter will provide their views on several federal court decisions including: Section 101 patent eligibility of human genes under *Myriad*, Section 102 novelty and prior public use of drugs under *Pronova Biopharma*, Written Description of enzyme variants under *Novozymes*, Patent Exhaustion under *Bowman*, parallel litigation and reexamination strategies under *Fresenius*, and more. They will put these cases into context and provide important advice on how they may impact both your prosecution and litigation strategies.

[READ MORE ABOUT THE EVENT](#)

Related Solutions

Litigation

Intellectual Property Litigation

You May Be Interested In



Managing Cyber Risks in 2024: Regulatory Compliance, Litigation Risk, Third-Party Cybersecurity Incident Exposure

APRIL 24, 2024

SPEAKING ENGAGEMENT



FIA Law & Compliance Division Conference 2024

APRIL 24–26, 2024

SPEAKING ENGAGEMENT





18th Annual Flagship Conference on Economic Sanctions Enforcement and Compliance

APRIL 29, 2024

SPEAKING ENGAGEMENT

[VIEW ALL EVENTS](#)